Related Experiment Video
Updated: May 7, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Recent Advances in the Management of EGFR-Mutated Advanced Non-Small Cell Lung Cancer-A Narrative Review
Prabhat Gautam Roy1, Davida Reingold2, Neha Pathak3
1All India Institute of Medical Sciences, New Delhi 110029, India.
Abstract:
The treatment landscape for EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) has evolved significantly with multiple combination regimens demonstrating superiority over single agent Osimertinib over the past two years. Recent trials such as FLAURA2 and MARIPOSA have explored intensified front-line regimens, with FLAURA2 demonstrating improvement in PFS with the addition of chemotherapy to Osimertinib and MARIPOSA, showing both a PFS and OS benefit with a novel combination regimen of Amivantamab and Lazertinib. However, these regimens are associated with significantly higher toxicity to patients and pose a huge financial and logistical burden to the health care system; therefore, treatment selection must therefore be individualized, considering disease biology, patient fitness, and toxicity burden. Post-progression strategies remain challenging due to resistance mechanisms like EGFR C797S mutations and MET amplification and the lack of data post-progression on novel first-line combinations. Ongoing trials are investigating fourth-generation EGFR TKIs, MET inhibitors, antibody-drug conjugates, and bispecific antibodies in subsequent lines. While regimens like Amivantamab-Lazertinib show promise even in second-line settings, toxicity, cost, and access remain barriers. As therapeutic options expand, biomarker-driven sequencing and personalized care will be critical to optimizing long-term outcomes in EGFR-mutated mNSCLC.
Insights
New combination therapies improve outcomes for EGFR-mutated non-small cell lung cancer (NSCLC). However, increased toxicity and cost necessitate individualized treatment selection and further research into post-progression strategies.
Area of Science:
- Oncology
- Medical Oncology
- Pharmacology
Background:
- The treatment of EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) has rapidly evolved.
- Recent trials show combination regimens outperform single-agent Osimertinib.
- Intensified front-line approaches like FLAURA2 and MARIPOSA demonstrate improved progression-free survival (PFS) and overall survival (OS).
Purpose of the Study:
- To review the evolving treatment landscape for EGFR-mutated mNSCLC.
- To discuss the benefits and challenges of novel combination regimens.
- To highlight the importance of individualized treatment selection and future therapeutic strategies.
Main Methods:
- Literature review of recent clinical trials (e.g., FLAURA2, MARIPOSA).
- Analysis of efficacy (PFS, OS) and toxicity data.
- Discussion of emerging resistance mechanisms and post-progression treatment options.
Main Results:
- Combination regimens (chemotherapy + Osimertinib, Amivantamab + Lazertinib) show superior PFS and OS compared to Osimertinib alone.
- These novel regimens are associated with higher toxicity, financial, and logistical burdens.
- Resistance mechanisms (e.g., EGFR C797S, MET amplification) complicate post-progression management.
Conclusions:
- Individualized treatment selection is crucial, considering disease biology, patient fitness, and toxicity.
- Biomarker-driven sequencing and personalized care are essential for optimizing long-term outcomes.
- Ongoing research into novel agents (4th-gen TKIs, MET inhibitors, ADCs, bispecific antibodies) is vital for future treatment advancements.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...